Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical Affairs, Janssen Biolo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
biosimilars
chronic inflammatory disease
treatment discontinuation
infliximab
treatment switching
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/fad32ee9734e4ce0b8c50a317d79e827
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares